Intravesical Suplatast Tosilate (IPD-1151T) Inhibits Experimental Bladder Inflammation

Journal of Urology

Volumn 177, Issue 3, 2007, Pages 1186-1190

  Boucher, W ^a   Kempuraj, D ^a   Cao, J ^a   Papaliodis, D ^a   Theoharides, T C ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bladder; cystitis; histamine; inflammation; interstitial; mast cells; tumor necrosis factor alpha

Indexed keywords

CARBACHOL; HISTAMINE; IMMUNOGLOBULIN E ANTIBODY; LIPOPOLYSACCHARIDE; SODIUM CHLORIDE; SUPLATAST TOSYLATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASSAY; BLADDER EMPTYING; BLOOD VESSEL PERMEABILITY; CATHETER; CELL ACTIVATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG SCREENING; EXPLANT; FEMALE; HISTAMINE RELEASE; INTERSTITIAL CYSTITIS; MALE; MEDIATOR RELEASE; MOUSE; NONHUMAN; PERITONEUM MAST CELL; PRIORITY JOURNAL; RAT; SKIN BLOOD VESSEL; UMBILICAL CORD BLOOD; URINE;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ARYLSULFONATES; CAPILLARY PERMEABILITY; CELL CULTURE TECHNIQUES; CYSTITIS, INTERSTITIAL; FEMALE; HISTAMINE ANTAGONISTS; HISTAMINE RELEASE; HUMANS; MALE; MAST CELLS; MICE; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; SKIN; SULFONIUM COMPOUNDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846860645     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.10.036     Document Type: Article

References (20)

1. Hanno P. Interstitial cystitis and related disorders. In: Walsh P.C., Retik A.B., Vaughan Jr. E.D., and Wein A.J. (Eds). Campbell's Urology. 8th ed. (2002), WB Saunders Co, Philadelphia 631-668
2. Lukban J.C., Whitmore K.E., and Sant G.R. Current management of interstitial cystitis. Urol Clin North Am 29 (2002) 649
3. Theoharides T., and Sant G.R. Immunomodulators for the treatment of interstitial cystitis. Urology 65 (2005) 633
4. Theoharides T.C., Kempuraj D., and Sant G.R. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology 57 (2001) 47
5. Tomaszewski J.E., Landis J.R., Russack V., Williams T.M., Wang L., Hardy C., et al. Biopsy features are associated with primary symptoms in interstitial cystitis: results from the interstitial cystitis database study. Urology 57 (2001) 67
6. Koda A., Yanagihara Y., and Matsuura N. IPD-1151T: a prototype drug for IgE antibody synthesis modulation. Agents Actions, suppl 34 (1991) 369
7. Shichijo M., Shimizu Y., Hiramatsu K., Togawa M., Inagaki N., Takagi K., et al. IPD-1151T (suplatast tosilate) inhibits interleukin (IL)-13 release but not IL-4 release from basophils. Jpn J Pharmacol 79 (1999) 501
8. Ueda T., Tamaki M., Ogawa O., Yamauchi T., and Yoshimura N. Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T. J Urol 164 (2000) 1917
9. Zhao G.D., Yokoyama A., Kohno N., Sakai K., Hamada H., and Hiwada K. Effect of suplatast tosilate (IPD-1151T) on a mouse model of asthma: inhibition of eosinophilic inflammation and bronchial hyperresponsiveness. Int Arch Allergy Immunol 121 (2000) 116
10. Gonzalez R.R., Fong T., Belmar N., Saban M., Felsen D., and Te A. Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis. J Urol 173 (2005) 630
11. Lytinas M., Kempuraj D., Huang M., Boucher W., Esposito P., and Theoharides T.C. Acute stress results in skin corticotropin-releasing hormone secretion, mast cell activation and vascular permeability, an effect mimicked by intradermal corticotropin-releasing hormone and inhibited by histamine-1 receptor antagonists. Int Arch Allergy Immunol 130 (2003) 224
12. Kempuraj D., Saito H., Kaneko A., Fukagawa K., Nakayama M., Toru H., et al. Characterization of mast cell-committed progenitors present in human umbilical cord blood. Blood 93 (1999) 3338
13. Malley S.E., and Vizzard M.A. Changes in urinary bladder cytokine mRNA and protein after cyclophosphamide-induced cystitis. Physiol Genomics 9 (2002) 5
14. Chen M.C., Blunt L.W., Pins M.R., and Klumpp D.J. Tumor necrosis factor promotes differential trafficking of bladder mast cells in neurogenic cystitis. J Urol 175 (2006) 754
15. Donelan J., Boucher W., Papadopoulou N., Lytinas M., Papaliodis D., Dobner P., et al. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 103 (2006) 7759
16. Alexacos N., Pang X., Boucher W., Cochrane D.E., Sant G.R., and Theoharides T.C. Neurotensin mediates rat bladder mast cell degranulation triggered by acute psychological stress. Urology 53 (1999) 1035
17. Theoharides T.C., and Sant G.R. Neuroimmune connections and regulation of function in the urinary bladder. In: Bienenstock J., Goetzl E., and Blennerhassett M. (Eds). Autonomic Neuroimmunology vol 15 (2003), Hardwood Academic Publishers, Lausanne, Switzerland 345-369
18. Yoshimura N., Seki S., Chancellor M.B., deGroat W.C., and Ueda T. Targeting afferent hyperexcitability for therapy of the painful bladder syndrome. Urology 59 (2002) 61
19. Theoharides T.C., and Cochrane D.E. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 146 (2004) 1
20. Batler R.A., Sengupta S., Forrestal S.G., Schaeffer A.J., and Klumpp D.J. Mast cell activation triggers a urothelial inflammatory response mediated by tumor necrosis factor-alpha. J Urol 168 (2002) 819